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The pathogenesis of lung disease in cystic ﬁbrosis is characterised by decreased airway surface liquid volume and subsequent
failure of normal mucociliary clearance. Mucus within the cystic ﬁbrosis airways is enriched in negatively charged matrices
composed of DNA released from colonizing bacteria or inﬂammatory cells, as well as F-actin and elevated concentrations of
anionic glycosaminoglycans. Therapies acting against airway mucus in cystic ﬁbrosis include aerosolized hypertonic saline. It has
been shown that hypertonic saline possesses mucolytic properties and aids mucociliary clearance by restoring the liquid layer
lining the airways. However, recent clinical and bench-top studies are beginning to broaden our view on the beneﬁcial eﬀects
of hypertonic saline, which now extend to include anti-infective as well as anti-inﬂammatory properties. This review aims to
discuss the described therapeutic beneﬁts of hypertonic saline and speciﬁcally to identify novel models of hypertonic saline action
independent of airway hydration.
1.Introduction
Cystic ﬁbrosis (CF) is a complex genetic disease with protean
manifestations, the most important being increased risk
of chronic lung disease resulting in terminal respiratory
failure [1]. CF is an autosomal recessive disorder caused by
mutations in the CF transmembrane conductance regulator
(CFTR) chloride channel. More than 1000 mutations in the
CFTR gene have been identiﬁed and result in misfolding
of the CFTR protein. Reported mutations can be broadly
categorised by class mutations which alter CFTR processing
(Classes I, II, and V) as well as those resulting from dysreg-
ulated chloride secretion (Classes III, IV, and VI) (Figure 1).
The commonest genetic defect in CFTR processing includes
the ΔF508 mutation, of which 90% of CF suﬀers carry one
copy [2]. Defects in CFTR protein function not only impact
upon cAMP-dependent chloride secretion but also result
in increased epithelial sodium channel- (ENaC-) mediated
ion absorption in the superﬁcial airway epithelium [3,
4]. As a consequence, increased water reabsorption across
airway epithelial cells leads to extreme dehydration of the
airway surface liquid layer, chronic mucostasis, and airﬂow
obstruction [5]. This thickened mucus provides an ideal
environment for bacterial infection in the respiratory tract
with Staphylococcus aureus (S. aureus) being a major bac-
terial pathogen in early years and Pseudomonas aeruginosa
(P. aeruginosa) a prominent pathogen in adult patients
[6, 7].
Dehydration of the airway surface liquid layer has been
implicated as the primary initiating event in CF-related
lung disease [9] and therapeutic interventions to improve
mucus clearance is a cornerstone of treatment in CF [10].
Such interventions include regular chest physiotherapy,
mucolytics such as dornase-alpha (DNase) [11] and also
aerosolized hypertonic saline (HTS; 3% to 7% NaCl) [12].
HTS is deﬁned as a solution possessing an osmotic pressure
greater than that of physiologic isotonic salt solution (0.9%
NaCl). Inhalation of HTS has been proposed to signiﬁcantly
improve mucociliary clearance [13] and the popularity of its
use has increased on the basis of a number of clinical trials
[14–17]. Several mechanisms have been proposed for the
observed eﬀectiveness including changes in the rheological
characteristics of the airway mucus [18], increasing airway
surface liquid hydration [19], inhibition of ENaC [20], as2 The Scientiﬁc World Journal
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Figure 1: Classiﬁcation of CFTR mutations. CFTR mutations are classiﬁed into six classes according to their eﬀect on CFTR function. Class
I mutations inhibit biosynthesis, while Class II mutations aﬀect protein processing. Milder mutations such as Class III, IV, and VI impair
CFTR channel function and Class V mutations aﬀect gene expression, adapted from Allen (1999) [8].
well as immunomodulatory eﬀects [21–23]. While a large
controlled study reported mild positive eﬀects of HTS on
lung function [24], further studies have hurled it back into
the limelight [25] and it is in this context that this review
will compile the evidence for the use of HTS in treatment of
individuals with CF.
2. PhysicalProperties of AirwayMucus
inCysticFibrosis
Within the normal lung, the mucous gel is largely made
up of mucin glycoproteins which are either secreted or cell
membrane tethered. Airway epithelial cells express three gel-
forming mucins including MUC2, MUC5AC, and MUC5B,
although MUC5AC and MUC5B are thought to be the
major gel-forming mucins in healthy airway secretions.
While the molecular mass of mucins in CF and healthy
control airway samples is comparable, the concentration of
MUC5AC and MUC5B in CF sputum is markedly decreased
[27]. This is of major importance and has prompted research
aimed at investigating both the cause-and-eﬀect relationship
leading to thick purulent mucus in the CF airways. The
primary cause of dehydrated thick mucus is increased water
reabsorption across CFTR defective airway epithelial cells.
However, a second reason for the thick viscous mucus in
CF is the enrichment of anionic polyelectrolytes including
DNA produced by colonizing bacteria or released from lysed
inﬂammatory cells [28, 29]. Moreover, F-actin released from
necrotic cells within the CF airways plays a major role in
the secondary polymer network of CF sputum [30]. By laser
scanning confocal microscopy, copolymers of DNA and F-
actin have been observed which are thought to inﬂuence
the viscoelasticity of CF sputa [31, 32]. In addition, elevated
concentrations of anionic glycosaminoglycans (GAGs) have
been found in mucus samples from children with CF [33]
(Figure 2). For example, signiﬁcantly increased bronchial
levels of hyaluronic acid have been reported [34], with
sputum concentrations 100-fold higher than in acute bron-
chitis. Moreover, CF sputum has been shown to contain
signiﬁcantly elevated levels of chondroitin [35] and heparan
sulphate [36]a n din vitro enzymatic digestion of GAGs
with chondroitinase ABC rather than protein digestion with
trypsin decreased viscoelasticity of CF purulent sputa [37].
Of importance, studies have also shown that mutations in
CFTR give rise to aberrant levels of sulphation. Particular
changes in GAG chains and sulphation patterns may allow
increasedinteractions,normallyofionicnature,withvarious
proteins including antimicrobial peptides [21] and proin-
ﬂammatory stimuli [36, 38–40]. Data supporting this phe-
nomenon have demonstrated synthesises of oversulphated
glycoconjugatesbyCFtissueinorganculture[41]andairway
epithelial cells [42, 43]. Fundamentally, regardless of the
exact or combined cause of increased viscosity, the thickened
mucus within the CF airways becomes detached from the
cilia and mucociliary transport is impaired, the major cause
of lung morbidity and mortality in CF. HTS is thought to act
bydrawingwaterfromCFTRdefectiveairwayepithelialcells,
thereby rehydrating the periciliary layer [44] and supporting
mucociliary clearance [25]( Figure 3). HTS is, therefore, oneThe Scientiﬁc World Journal 3
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Figure 2: Mucus properties in the CF lung. (a) Mucus in a healthy lung is made up of a network of mucin ﬁlaments consisting of highly
glycosylated mucin monomers that are crosslinked by disulphide bonds. Mucin ﬁlaments are bound together by noncovalent bonds (red
dotted lines) such as van der Waals forces. (b) In the CF airways, mucus viscosity is increased by DNA and actin (red) that are released from
necrotic neutrophils and aggregate into bundles. Glycosaminoglycans (GAGs, depicted in brown) which are important for regulation of cell
interactions have been found to be upregulated and altered in CF. Adapted from Rogers (2007) [26].
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Figure 3: Eﬀect of hypertonic saline on the airway surface liquid (ASL) in CF. (a) In healthy airway epithelia, CFTR is intact and plays a vital
role in regulating hydration of the ASL that consists of the periciliary layer (PCL) and the mucus layer. (b) Due to defective CFTR in CF, Cl￿
secretion is impaired and Na+ absorption through ENaC is upregulated resulting in dehydration of the ASL with thick mucus accumulating
and causing the PCL to collapse. (c) Treatment with hypertonic saline is proposed to reduce mucus viscosity and aids its clearance by various
mechanisms. The high salt concentration encourages osmosis of water into the ASL and thereby rehydrates the mucus and partially restores
the PCL allowing for easier clearance of mucus. Additionally, the high ionic strength weakens ionic bonds between negatively charged GAGs
and thus reduces the viscosity of the mucus.
of the ﬁrst treatments whose mechanism of action bypasses
the basic CFTR defect.
3. HypertonicSalineinTreatmentof
CFAirwayDisease
In 2006, Elkins and colleagues from the National Hypertonic
SalineinCysticFibrosisStudyGroupperformedatrialof164
patientswhowererandomised toreceive7%HTSorisotonic
0.9% saline. Results revealed no signiﬁcant diﬀerence in the
rate of change of lung function (as measured by forced
vital capacity and forced expiratory volume in one second
(FEV1)),yettheabsolutediﬀerenceinlungfunctionbetween
groups was signiﬁcant (P = 0.03). Of major importance,
this study oﬀered the ﬁrst evidence for the long-term eﬃcacy
of HTS and showed a marked reduction in the number
of exacerbations over patients who received isotonic saline
solution [24]. Likewise, in a study performed by Donaldson
and colleagues (2006), patients who received HTS (7% four
times daily for 14 days with or without amiloride (inhibitor
of ENaC)) demonstrated improved mucociliary clearance
and FEV1 when given alone rather than in conjugation
with amiloride [25]. The eﬀect of HTS in this latter study
could only be compared to baseline as no isotonic saline4 The Scientiﬁc World Journal
control group was included [25], however, their conclusions
were echoed in a further study by use of radioaerosol
technology [13]. Within this latter study, patients with CF
treated with HTS had signiﬁcantly increased mucociliary
clearance compared to patients treated with amiloride or
isotonic saline [13]. A further consideration when debating
the eﬀectiveness of HTS is the volume administered. In
studies performed by Elkins et al., [24] and Donaldson et
al., [25]4a n d5m Lo fH T Sw e r ea e r o s o l i z e d ,r e s p e c t i v e l y ,
and their studies recorded smaller improvements in lung
function compared to Ballmann and von der Hardt [15]
and Eng et al., [16] who delivered 10mL of HTS. Moreover,
in a recent stratiﬁed assessment of the impact of HTS on
CF pulmonary exacerbations, Dmello et al., (2011) reviewed
340 cases of which 99 involved HTS treatment. By the
use of multivariate logistic regression analysis, their results
supported treatment with HTS in the context of reducing
pulmonary exacerbations associated with CF lung disease
[45].
HTS has been shown to increase mucociliary clearance
in adults with CF [13, 25, 44], but in contrast, did not sig-
niﬁcantly improve mucociliary clearance in children with CF
( m e d i a na g e1 0 . 5y e a r s )[ 46]. The diﬀerences in therapeutic
eﬃcacy of HTS between adults and children may, however,
relate to the degree of airway disease. Nevertheless, if HTS
can improve mucociliary clearance by impacting upon the
fundamental hydration defect, it may prove most successful
in treatment of juvenile and young teenage patients before
airway disease takes hold. To this end, in a recent study of
18 young participants (12–30 months of age) who received
7% HTS twice daily for 14 days, Rosenfeld and coworkers
(2011) showed that HTS was well tolerated with high
patient adherence [47]. In addition, lung clearance index,
a measure of lung physiology derived from multiple breath
washout tests, improved in paediatric patients (6–18 years)
treated with 7% HTS compared to isotonic saline (0.9%)
solution [14]. Furthermore, a study assessing the safety
and tolerability of inhaled HTS pretreated with nebulised
beta adrenergic agonists (salbutamol) in preschool children
(mean age 5.7 ± 0.8 years) and infants (mean age 1.6 ±
1 years) with CF showed no clinically important decrease
in FEV1, FVC, or FEF25−75 after HTS treatment. Only
one patient had a clinically signiﬁcant decrease (>20%) in
pulmonary function, however, this patient had a preexisting
diagnosis of bronchial hyperactivity [48].
Induced cough may also be an important mechanism
by which HTS improves mucociliary clearance in patients
with CF. Patients treated with HTS have more cough
episodes following treatment [48] and this may in itself
improve mucociliary clearance by generating high sheer
stress which promotes clearance of mucus from the airway
surface [49]. The optimal dose of HTS is still a matter of
debate with increasing doses (from 3% to 7%) requiring
increasing nebulisation times, a potentially unrealistic treat-
ment burden on patients [50], with compliance reported
at only 64% [24]. On this point, coaerosolisation of 7%
HTS with 0.1% hyaluronate has been shown to signiﬁcantly
improve tolerability and pleasantness compared to HTS
alone [51]. Moreover, the eﬀect of HTS on mucociliary
clearance appears dose dependent. In a study performed
by Robinson and colleagues (1997), the levels of sputum
cleared over 90 minutes increased as the concentration of
NaCl incrementally increased (0.9%, 3%, 7%, and 12%).
However, patients experience considerable oropharyngeal
irritation with concentrations approaching 12% making this
the upper limit of tolerability in most patients.
Improvements in mucociliary clearance by HTS may
provide a useful adjunct to improve the amount of sputum
availableformicrobiologicalevaluationfrompatientssuchas
thosewithmilddiseaseoryoungchildrenwhohavediﬃculty
expectorating sputum. These patients often undergo ﬂexible
bronchoscopy and bronchoalveolar lavage to obtain ade-
quatesamplevolumesforcultureandsensitivity.Thus,HTS-
induced sputum may be clinically useful by increasing the
volumeofexpectoratedsputumavailableformicrobiological
culture [52], as previously shown for children with CF [53].
4. The Effect of HypertonicSalineon
Infection and Inﬂammation
HTS does improve mucociliary clearance and lung function
in patients with CF but a number of studies have also
explored the possibility that HTS may impact upon the
inﬂammatory response within the airways and in partic-
ular levels of the proinﬂammatory neutrophil chemokine,
interleukin(IL)-8.Inthelong-termcontrolledtrialofinhaled
HTS in patients with CF performed by Elkins and colleagues
(2006), measurements of the proinﬂammatory cytokines
IL-6, IL-8, IL-10, and tumour necrosis factor-alpha (TNF-
alpha) were made in sputum at the time of screening and
several later points until 48 weeks after the implementation
of HTS nebulisation [24]. However, no signiﬁcant diﬀerence
was found in sputum levels between these groups (IL-6,
P = 0.94; IL-8, P = 0.36; IL-10, P = 0.81, and TNF-
alpha, P = 0.38), although all samples tested were from
the postrandomisation period and no direct comparison was
made between pre- and postnebulisation sputum samples or
from samples taken before starting HTS treatment. A second
study by Aitken et al., (2003) measured IL-8 and neutrophil
numbersinCFsputumat5sequentialtimepointsduringthe
20 minutes after HTS nebulisation. Although the percentage
ofneutrophilsdecreased(89 ±5%to86 ±4%;P = 0.03),the
concentrationofIL-8remainedthe same[54].Thebeneﬁcial
eﬀect of HTS on reducing airway neutrophil numbers was
also observed in an animal model of induced lung injury,
whereupon 7.5% HTS signiﬁcantly reduced cell counts in
bronchial lavage ﬂuid from 46.8 ± 4.4 × 103 to 24.5 ± 5.9 ×
103 cells/mL (P<0.05).
Unexpectedly, it has also been shown that HTS condi-
tions may actually increase IL-8 production by CF gland cells
via the NF-κBp a t h w a y[ 55] and IL-8 expression in human
bronchial epithelial cells via p38 mitogen-activated protein
kinases activation [56]. Moreover, a study of individuals
with asthma or COPD (10 patients in each group) revealed
that inhalation of HTS caused low levels of inﬂammation
in the airways with an increase in the levels of IL-6 and
TNF-alpha recorded in exhaled breath condensate [57]. InThe Scientiﬁc World Journal 5
contrast, on a cellular level, the beneﬁcial eﬀects of HTS were
found to include reduced arachidonic acid and leukotriene-
B4-induced priming of the respiratory burst of isolated
neutrophils [58] and suppression of mTOR activity in
mononuclear cells [59]. In additional studies, the beneﬁcial
eﬀects of HTS were revealed as HTS increased levels of
glutathione and thiocyanate which are protective against
oxidants in the lung [60].
A further study by Suri et al., (2001) compared the eﬀects
of HTS and dornase-alpha on inﬂammatory mediators and
found no signiﬁcant diﬀerence in CF sputum IL-8 levels
before and 18 hours after HTS nebulisation [17]. Indeed,
it has been proposed that rhDNAse may actually promote
inﬂammation by liberating cationic mediators bound to
e x t r a c e l l u l a rD N As u c ha sp r o t e a s e sa sw e l la sa c t i v eI L -
8, which can potentiate neutrophilic inﬂammation causing
further lung damage [61, 62]. This latter point is obviously
a concern, but research by our group has shown that when
IL-8 is released from negatively charged matrices including
GAGs this renders the chemokine susceptible to proteolysis
and that there is a period of time during which IL-8 levels
are signiﬁcantly decreased after HTS treatment [23]. As per
results demonstrated by Frevert et al., (2003) [63], within
our study, we found that IL-8 in CF bronchial lavage ﬂuid
is present in high molecular weight complexes involving
GAGs including heparan and chondroitin sulphate [23]. By
disrupting ionic interactions between IL-8 and GAGs, HTS
displaced IL-8 from GAG matrices rendering the chemokine
susceptible to proteolytic degradation by neutrophil elastase
thereby impacting upon inﬂammation [23]. Another key
inﬂammatory mediator that is found in the CF lung and
thought to play an important role in the pathophysiology
of CF lung disease is the antimicrobial peptide cathelicidin
(LL-37) [64, 65]. LL-37 demonstrates antimicrobial activity
against an array of bacteria including S. aureus, Escherichia
coli [66], and P. aeruginosa [21] and although present in high
concentrations within the CF lung, the activity of LL-37 is
inhibited by binding to GAGs [66]. Release of LL-37 within
CFBALFwasbroughtaboutbyenzymaticdigestionofGAGs
(by hyaluronidase, chondroitinase ABC, or heparinase II)
thereby increasing the bactericidal eﬃciency of CF BALF
against Pseudomonas and Staphylococcus bacteria [21]. In
turn, HTS may also improve lung function by disrupting
electrostatic interactions between GAGs and antimicrobial
peptides. In support of this theory, in vivo L L - 3 7i nC F
sputum was liberated from GAGs following nebulised HTS
(7%) resulting in increased antimicrobial eﬀect [21]. Thus,
HTS therapy may directly impact upon the viability of
bacteria within the CF airways. In fact, the eﬀect of HTS
on P. aeruginosa appears multifold, with high ionic strength
aﬀecting not only ﬂagellin-mediated motility [22], but also
viability of the mucoid subpopulation [67].
5. How Does HypertonicSaline Compare
with Other Treatments?
While HTS is cost eﬀective [68] and has been proposed
to enhance mucociliary clearance and lung function in CF,
other mucus mobilising therapies that have been evaluated
include dornase-alpha [69], inhaled mannitol [70], gelsolin
that severs actin ﬁlaments [30] and thiol derivatives such as
n-acetylcysteine, although the clinical beneﬁts of the latter
treatment are unclear [71]. As high concentrations of DNA
contribute to the viscosity of airway secretions, treatment
with dornase-alpha, an enzyme which cleaves DNA poly-
mers, results in a signiﬁcant decrease in the viscosity of
mucopurulent sputum [72]. Randomised controlled trials
have demonstrated an improvement in FEV1 in patients
treated with dornase-alpha [73–75] and although it appears
more eﬀective than HTS, some variation in the individual
patient response was evident [76]. A small randomised study
of 14 patients by Ballmann and Von Der Hardt, showed a
mean increase in FEV1 of 7.7% in those treated with HTS
in comparison to 9.3% in individuals treated with dornase-
alpha [15]. A larger study of 48 children randomised to 12
weeksofdailydornase-alpha(2.5mg),alternatedaydornase-
alpha, and twice daily HTS (7%) demonstrated a mean
increase in FEV1 of 16% (SD 25%), 14% (SD 22%), and 3%
(SD21%)ineachofthetreatmentgroups,respectively.These
studies strongly suggest that dornase-alpha is more eﬀective
than HTS in this setting [17].
Inhaled mannitol therapy has been proposed as an
additional strategy to improve the airway surface hydration
andmucociliaryclearanceinpatientswithCF.Mannitolisan
osmotic agent with a high molecular weight which improves
airway surface hydration by slow inﬂux of water through a
pericellular pathway [70]. Earlier studies have shown that
mannitol improved mucociliary clearance in patients with
asthma and non-CF-related bronchiectasis [77, 78]. A two-
week course of inhaled mannitol in patients with CF resulted
in an increase in mean FEV1 from baseline of 7% (95%
conﬁdence interval, 3.3 to 10.7) as well as mean FEF25−75
by 15.5% (95% conﬁdence interval, −6.5 to 24.6) compared
with placebo [79]. While an international trial assessing the
eﬀectofinhaleddrypowdermannitolonlungfunctioninCF
showed a sustained clinical beneﬁt of mannitol irrespective
of rhDNase [80], there have been no large randomised
trials comparing the eﬀect of HTS versus mannitol in the
treatment of patients. A small study, however, comparing
inhaledHTSandmannitoltoplacebo,showedthatbothHTS
and mannitol demonstrated an improvement in bronchial
mucus clearance in the postintervention period (8.7 ± 3.3%
and 10.0 ± 2.3% resp.) [81].
6. HypertonicSalineinTreatmentof
Other AirwayDiseases
While the focus of this review has been on CF-related
bronchiectasis, non-CF-related bronchiectasis is a common
clinical condition and is being recognised much more
frequently with a reported prevalence in the United States
of over 110,000. Whereas several studies have demonstrated
beneﬁts of HTS in CF, there are preliminary data regarding
the therapeutic beneﬁts of HTS in patients with non-CF
bronchiectasis that are relevant to this review. In a double-
blinded study of 96 infants receiving repeated doses of6 The Scientiﬁc World Journal
Table 1: The reported eﬀects of hypertonic saline on infection and inﬂammation.
HTS treatment Patients sample or cells Eﬀect after HTS Reference
7% HTS Patients with CF Higher FEV1 and FVC, less pulmonary
exacerbations Elkins et al. 2006 [24]
3% HTS Sputum of patients with CF
Surfactant protein A increased;
neutrophil counts, Staphylococcus aureus
and non-mucoid Pseudomonas slightly
decreased.
Aitken et al. 2003 [54]
Hypertonic medium
Human bronchial gland cells
from CF and healthy controls
(isolated from brushings)
Increased NaCl increased IL-8, but higher
in CF cells (NF-κBp a t h w a ya c t i v a t e d ) Tabary et al. 2000 [55]
Hyperosmolarity
(NaCl or mannitol,
up to 6x normal)
Human bronchial epithelial cells Increased IL-8 release via p38 and JNK
pathway Hashimoto et al. 1999 [56]
4.5% HTS
Exhaled breath condensate of
patients with asthma or COPD
and healthy controls
Greater IL-6 and TNF-alpha
concentration, lower pH.
Carpagnano et al. 2005
[57]
Hypertonic medium Peripheral blood neutrophils
HTS inhibited neutrophil priming of
respiratory burst by LTB4 and
arachidonic acid
Lee et al. 2011 [58]
Hypertonic medium Peripheral blood mononuclear
cells
Reduced LPS induced mTOR pathway
activation in HTS treated cells Schaeﬀer et al. 2010 [59]
7% HTS Bronchial samples Increased antioxidant levels in BAL ﬂuid Gould et al. 2010 [60]
7% HTS Sputum from patients with CF Decreased IL-8 concentration in sputum
after HTS Reeves et al. 2011 [23]
7% HTS Sputum from patients with CF
LL-37 complexation to GAGs was
decreased after HTS and antimicrobial
properties of sputa restored
Bergsson et al. 2009 [21]
2–7% HTS in culture
medium
Pseudomonas strain PA01 and
mucoid strain FRD1
Reduced motility and growth of all
strains tested Havasi et al. 2008 [22]
0–0.8M NaCl added
to medium
Pseudomonas strain PA01 and
mucA mutant
MucA mutant less resistant to osmotic
stress Behrends et al. 2010 [67]
nebulised 3% HTS or isotonic saline, those treated with HTS
had a clinically relevant 26% reduction in hospital length of
stay [82]. In a small study of 24 individuals with stable non-
CF bronchiectasis, Kellett and colleagues (2005) reported
that patients treated with 7% HTS showed signiﬁcantly
higher sputum weights, reduced sputum viscosity, and ease
of expectoration than those treated with isotonic saline
(P<0.0001). Median FEV1 and FVC demonstrated a
statistically signiﬁcant improvement (P = 0.043) [83]. In
addition, a recent study by the same author reported that
HTS was eﬀective in decreasing sputum retention in patients
with non-CF bronchiectasis, resulting in improved lung
function and a reduction in annualised antibiotic usage and
emergency health care utilisation [84].
Bronchiolitis is the leading cause of hospitalisation for
infants involving a viral infection that begins as an upper-
respiratory infection and then progresses to involve the
lower small airways of the lung. A study by Al-Ansari et
al., (2010) evaluated the clinical utility of HTS compared
to isotonic saline in treatment of children with bronchi-
olitis and demonstrated that nebulisation with 5% HTS
improved the bronchiolitis severity score in patients with
viral bronchiolitis compared to treatment with 0.9% and
3% saline [85]. HTS has been also been suggested for
use in chronic pulmonary disease (COPD), asthma, and
pneumonia [86–90]. A study into the safety of sputum
induction in 100 individuals with COPD reported that HTS
could be used by tailoring treatment to a patient’s speciﬁc
needs in moderate-to-severe COPD [90]. Moreover, in a
multicenter study of 79 subjects with moderate-to-severe
asthma, indices of inﬂammation (IL-8, myeloperoxidase,
eosinophilic cationic protein, and neutrophil elastase) in
HTS-induced sputum were as reproducible as those present
in sputum postmethacholine PC20 treatment [87].
7. Conclusion
Therapies acting against airway mucus in CF include
dextran, nacystelyn [91], and gelsolin [30] which possess
mucolytic properties, but evidence that these agents cause
sustained relief from airway obstruction in chronic lung
disease is lacking. On comparing the beneﬁcial eﬀects
of aerosol administration of dornase-alpha to HTS [17],
dornase-alpha improved FEV1 and reduced the frequency
of pulmonary exacerbations [73] but illustrated a combined
eﬀect when administered with HTS for the clearance of
CF purulent sputa [18]. HTS treatment is associated with
an improvement in lung function and marked beneﬁts
with respect to exacerbations (Table 1)[ 24, 25, 92, 93]. AsThe Scientiﬁc World Journal 7
Improved mucociliary 
clearance
Immunomodulatory
123
+
Hypertonic Saline
ENaC
CFTR
ENaC
CFTR
ENaC
CFTR
ENaC
CFTR
Cl−
Cl− Cl−
Cl−
Na+
Na+
Na+
Na+ Na+
Na+ Na+ Na+
IL-8
IL-8
− −
+
IL-37
Proteolyic
degradation
Antimicrobial
Figure 4: Schematic representation of the antimicrobial, immunomodulatory and mucolytic properties of HTS. (1) HTS draws water into
the dehydated CF periciliary layer and improves mucus rheology and enhances mucociliary clearance. (2) LL-37, an antimicrobial protein
that is inhibited by GAGs, is released by HTS via disruption of the electrostatic interaction between LL-37 and GAGs. (3) HTS liberates IL-8
from anionic matrices (GAGs) rendering the chemokine susceptible to proteolytic degradation by neutrophil elastase, thereby decreasing
inﬂammation.
declared by Elkins and Bye (2006), “HTS appears broadly
applicable as an inexpensive therapy for most patients with
CF” [92] and of tremendous value on an individual basis for
patients intolerant of dornase-alpha [12].
In a similar fashion to mannitol [94], the positive
eﬀect of nebulised HTS on mucociliary clearance is based
on restoring the liquid layer lining the airways [26, 95].
This simple scheme, which for many years has served as a
satisfactory working hypothesis, may not be the full story.
Studies are now revealing that HTS can also function by
releasing essential antimicrobial and immune molecules
from complexation with ionic matrices thus improving
both antimicrobial eﬃciency and resolution of inﬂamma-
tion (Figure 4). These observations suggest that HTS has
beneﬁcial therapeutic eﬀects other than simply increasing
mucociliary clearance and thus further investigations of the
potential mechanisms of this currently available therapy is
crucially required.
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